GLP-1 Meds Slash Amputations and Deaths in Diabetes Patients with PAD

A groundbreaking study published in the Journal of the American Heart Association reveals that GLP-1 receptor agonists (GLP-1 RAs), commonly used for Type 2 diabetes and weight loss, significantly reduce deaths, amputations, and hospitalizations in patients with peripheral artery disease (PAD). The research, led by Dr. Aravinda Nanjundappa of the Cleveland Clinic, analyzed over 2,000 adults with both conditions, finding that GLP-1 RAs outperformed metformin in key outcomes: a 26% reduction in all-cause mortality, 13% fewer hospitalizations, up to 48% fewer amputations, and a 36% decrease in procedures to restore leg blood flow. However, rates of heart attack, stroke, and kidney events were similar between groups.

The benefits were most pronounced in patients with severe PAD, including chronic limb-threatening ischemia, and those with obesity (BMI ≥30). Dr. Akiva Rosenzveig noted that obesity and PAD share pathways of inflammation and vascular dysfunction, which GLP-1 RAs may counter. The study, using the TriNetX database, matched 2,133 patients per group, with 63% white, 23% Black, and 45% women. Limitations include potential coding errors in electronic health records and the inability to prove causation.

Dr. Joshua Joseph, an American Heart Association expert, emphasized the need for further research to confirm mechanisms, such as inflammation reduction, and to explore benefits for PAD patients without diabetes. With an estimated 29.5 million U.S. adults with Type 2 diabetes and 12.5 million with PAD, these findings could reshape treatment paradigms. The American Heart Association's 2026 statistics highlight the scale of the issue, and this study offers hope for better outcomes in a high-risk population. For more details, see the original release on NEWMEDIAWIRE.